Bionomics Limited (ASX:BNO, OTCQX:BNOEF) has met all primary and secondary endpoints for the Phase 1 of its BNC210 treatment for anxiety and depression.
No adverse effects on cognition or emotional stability and no abuse potential were indicated with BNC210 significantly reducing the effect of nicotine.
The results support continued development of BNC210.
In the study, a total of 54 healthy volunteers were enrolled and dosed for eight consecutive days, with 42 subjects receiving BNC210 and 12 receiving a placebo.
The company is also continuing the Phase 2 trial for the use of BNC210 as a treatment for Generalized Anxiety Disorder. Results are expected in Q3 2016.
Bionomics is well funded with $27.4 million in cash as at 30th June 2015.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.